independent set of specimens. This approach is to be commended because the validation set was completely independent of the development sets. The validation set was from the prospective cohort study Eastern Cooperative Oncology Group E5194. The patients accrued in to the study met rigorous selection criteria: 1) low-or intermediate-grade DCIS, tumor size less than or equal to 2.5 cm (cohort 1); or 2) high-grade DCIS, tumor size less than or equal to 1.0 cm (cohort 2). The sample available for validation was comprised of 327 individual patient specimens from the 670 enrolled. Although the authors compare characteristics of the available with the unavailable specimens, a concern of selection bias does enter in at this juncture. Furthermore, the structure of E5194 already provides a strong level of selection bias because patients with larger or more aggressive DCIS had either radiation after lumpectomy or mastectomy. Unfortunately, the authors do not provide any details of the number of individuals assessed before enrollment into E5194. This would be useful, especially to know the number of women ineligible for study because of grade and/or size criteria as opposed to those not interested in participation. The generalizability of the results of the assay is, therefore, still to be determined. The authors do rightly caution against extrapolation outside of the entry criteria of E5194 in their conclusion. However, clinical application frequently speeds ahead of prudence. All pathology specimens that had been centrally reviewed in the original study were re-reviewed by two expert pathologists.
Another limitation of the study is that patients were included who took tamoxifen. Use of tamoxifen was not randomized. The authors control for this by performing adjustments with and without tamoxifen use, but caution is advised.
The 10-year ipsilateral breast event risk was defined as the primary outcome for the continuous DCIS Score. Unfortunately, median follow-up of the cohort was 8.8 years (range = 0.2-13.2 years). The original 10-year recurrence risks were 14.6% for cohort 1 and 19.0% for cohort 2. The DCIS Score for the low-, intermediate-, and highrisk groups were 10.6%, 26.7%, and 25.9% (log rank P = .006), respectively, and for an invasive ipsilateral breast event were 3.7%, 12.3%, and 19.2%, respectively. In multivariable analyses, tumor size and menopausal status remained significant (both P ≤ .02). A comparison with the Van Nuys Prognostic Index in Table 3 shows that there was little discrimination in the E5194 dataset by low or intermediate score, documenting therefore an improvement in ipsilateral breast event risk discrimination for the DCIS score.
The question is will women find this information of use when making a treatment decision in conjunction with their physicians. For some, such as the woman recently featured in the New England Journal of Medicine piece who chose bilateral mastectomies, any risk of recurrence over that from bilateral mastectomies may be perceived as too high (5). However, for others, such as a postmenopausal woman with a low DCIS Score and a small tumor, no further treatment and careful follow-up with appropriate imaging is very reasonable.
The authors are to be commended for their thorough work adhering to a stringent design. The limitation they faced in terms of lack of specimens is one that is well recognized, and efforts from the National Cancer Institute and others to rectify this are important for future scientific advances. The clinical applicability of this assay for all women who present with DCIS remains to be determined. This assay does appear to be a step forward.
randomized clinical studies led by the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial (5) (6) (7) (8) .
Although the use of BCS for DCIS is not a debatable issue, the need for adjuvant radiation therapy (RT) is (9) . There is substantial heterogeneity in the management of DCIS. Patients at low enough risk that they do not require RT after BCS have not been identified reliably in prospective clinical trials (10) (11) (12) . However, four, large, prospective, randomized clinical trials have studied the benefit of adding RT after BCS in the treatment of DCIS. The addition of RT after BCS in these trials was shown to reduce the risk of local invasive recurrence and overall recurrence by 50% without a survival benefit (13) . The NSABP B-24 trial (14, 15) and the United Kingdom, Australia, New Zealand trial (16) evaluated both RT and tamoxifen in the treatment of DCIS. Although ipsilateral breast tumor recurrence (IBTR) is reduced by 25% (14,15) with tamoxifen, it is not a substitute for RT after excision of DCIS (5, 14, (16) (17) (18) (19) (20) .
The Eastern Cooperative Oncology Group (ECOG) E5194 trial (21) studied patients with nonpalpable low-/intermediate-risk and high-risk DCIS treated with excision alone with or without tamoxifen. The low-or intermediate-grade DCIS was defined as less than or equal to 2.5 cm, whereas high-grade DCIS was defined as less than or equal to 1 cm in greatest dimension. Acceptable minimum margin width was greater than or equal to 3 mm. At 7 years of follow-up, the trial showed an overall local recurrence rate of 10.5% in the low-risk population and a rate of 18% in the highrisk population (21) . Radiation Therapy Oncology Group (RTOG) 9084 (22) studied RT vs observation for the management of "goodrisk" DCIS. Eligibility criteria included low-or intermediate-grade DCIS detected mammographically or found incidentally, with size less than or equal to 2.5 cm and margins greater than 3 mm. Eightyear results showed local recurrence rates of 3.2% in the excisionalone group and 0.4% in the excision-followed-by-RT group, demonstrating the benefit of radiation for the "good risk" DCIS.
These studies generated questions about the use of RT for locally excised DCIS and whether there is a subset of patients who do not require RT. The need to better identify the risk of recurrence associated with DCIS has led to the development of the DCIS Score (23). This genomic-based score is the first attempt to predict local recurrence regardless of tamoxifen use. The DCIS Score was developed from analysis of the results of multiple correlative science studies that compared gene expression in invasive breast cancer (IBC) and DCIS. The analysis revealed that the tumor biology of IBC and DCIS is similar, with differences seen in the distribution of proliferation genes. Seven genes that predicted recurrence risk and five reference genes were selected for the DCIS Score. In this issue of the Journal, Solin et al. aimed to determine whether there is an association between the DCIS Score and the risk of an IBE (23) . The ECOG E5194 study was used to validate the DCIS score. This methodology was not used to identify patients who are necessarily at low risk, but rather to identify what the risk would be based on surgical excision alone. Excluding the DCIS Score, in the study's multivariable analysis of risk for an IBE, the most statistically significant predictors of recurrence were tumor size and postmenopausal status. When the DCIS Score was included, it proved to be the most statistically significant predictor of recurrence. The study reports that the DCIS Score, when adjusted for tamoxifen use, was statistically significantly associated with the development of an IBE. The 10-year risk of IBE increased continuously as the DCIS Score increased (23) .
The DCIS Score does not make recommendations regarding RT. Rather, it provides information that assists the decisionmaking process for the clinician and patient. The score predicts the risk of recurrence without RT; however, the clinician may advise the patient that the calculated risk is decreased further with the addition of RT. Based on potential benefit, a decision can be made on how to proceed. The patient must be counseled that whether the recurrence is noninvasive or an IBC with possible lymph node metastasis is not predicted by the DCIS Score. Such information would be valuable because an invasive IBE is associated with an increase in mortality (14) . Although the information provided by the DCIS Score may be useful in the correct setting and application, it is not a definitive guide. The study by Solin et al. (23) does not address the use or lack of RT and has not yet been validated against DCIS treated with whole breast irradiation. The data used to develop the DCIS Score may be affected by the low number of estrogen receptor (ER)-negative and Her2neu (H2N)-positive patients included, small subgroup sample sizes, the need to develop its algorithm based on mixed IBC and DCIS samples, and limited patients who have taken tamoxifen. This is important because H2N-positive DCIS has historically been associated with high-risk DCIS lesions (24) ; this subject is currently being evaluated in the NSABP B-43 trial (8) . Tamoxifen use and its substantial benefit in ER-positive DCIS should be part of the decision for treatment.
In conclusion, DCIS shares genetic similarities with IBC. Patients that will not progress to invasive cancer are difficult to predict; therefore, biomarkers indicative of risk recurrence are needed. In this issue of the Journal, Hoffman et al. (1) explore one of the many unanswered questions confronting newly diagnosed prostate cancer patients: Which definitive treatment is superior-radical prostatectomy (RP) or external beam radiotherapy (EBRT)? The authors analyzed an observational cohort from the populationbased Prostate Cancer Outcomes Study treated in the mid-1990s, and the resulting data suggested a survival benefit associated with RP over EBRT (1) . A propensity score analysis was used to adjust for treatment selection bias in this cohort of men aged 55 to 74 years with clinically localized disease. In men with high-risk tumors (Gleason score ≥ 8 or prostate-specific antigen > 10), both overall and prostate cancer-specific mortality were statistically significantly lower in the group that received RP than the group that received EBRT. In men with low-risk tumors (Gleason score ≤ 6 and prostate-specific antigen ≤ 10), there was no difference in prostate cancer mortality and a modest but statistically significant difference in overall mortality. Notably, this analysis did not include intermediate-risk patients. It is also interesting to note that acceptance of active surveillance as a treatment option for most, if not all, patients with low-volume, low-risk disease is much greater now that it was when this study was initiated.
Although this analysis is provocative, it has several limitations. First and foremost, as in most studies comparing RP and EBRT, there is substantial concern that patients who receive EBRT have far more serious comorbidities and potentially more advanced local disease. Although this analysis employed propensity scoring
